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What is already known about this topic? Small airway dysfunction is a disease feature in asthma.
What does this article add to our knowledge? Older age, obesity, and the related systemic inflammation, type 2
inflammation, and smoking are independent predictors of SAD. Obesity contributes to SAD in itself and through systemic
inflammation. Small airway dysfunction affects physical activity mainly through symptom control. The effect of obesity on
symptom control and physical activity is partially mediated by SAD. Obesity and physical activity also affect symptom
control independently from SAD.
How does this study impact current management guidelines? This knowledge advances our understanding of the
relations among SAD, asthma control, and physical activity. Symptom control could be achieved by treating SAD by
reducing airway inflammation, through weight loss, and by increasing physical activity.ungenClinic Grosshansdorf, Airway Research Center North, German Center for
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2 ABDO ETALAbbreviations used
ACT- Asthma control testATLANTIS- Assessment of Small Airways Involvement in Asthma
BMI- Body mass index
FDR- Frequency dependence of resistance
FeNO- Fractional exhaled nitric oxide
GINAT- the Global Initiative for Asthma
hsCRP- High-sensitivity C-reactive proteinIOS- Impulse oscillometry
LCI- Lung clearance index
SAD- Small airway dysfunction
SEM- Structural equation modeling
SPD- steps per dayBACKGROUND: Little is known about the role of small airway
dysfunction (SAD) and its complex relation with asthma control
and physical activity (PA).
OBJECTIVE: To investigate the interrelations among SAD, risk
factors for asthma severity, symptom control, and PA.
METHODS: We assessed SAD by impulse oscillometry and
other sophisticated lung function measures including inert gas
washout in adults with asthma (mild to moderate, n [ 140;
severe, n [ 128) and 69 healthy controls from the All Age
Asthma Cohort. We evaluated SAD prevalence and its
interrelation with risk factors for asthma severity (older age,
obesity, and smoking), type 2 inflammation (sputum and blood
eosinophils, fractional exhaled nitric oxide), systemic
inflammation (high-sensitivity C-reactive protein), asthma
control (AC), and PA (accelerometer for 1 week). We applied a
clinical model based on structural equation modeling that
integrated causal pathways among these clinical variables.
RESULTS: The prevalence of SAD ranged from 75% to 90% in
patients with severe asthma and from 53% to 64% in mild to
moderate asthma. Severe SAD was associated with poor AC and
low PA. Structural equation modeling indicated that age, obesity,
obesity-related systemic inflammation, T2 inflammation, and
smoking are independent predictors of SAD. Small airway
dysfunction was the main determinant factor of AC, which in turn
affected PA. Obesity affected AC directly and through its contri-
bution to SAD and low PA. In addition, PA had bidirectional
associations with obesity, SAD, and AC. Structural equation
modeling also indicated interrelations among distal airflow limi-
tation, air trapping, and ventilation heterogeneity.
CONCLUSIONS: Small airway dysfunction is a highly prevalent
key feature of asthma that interrelates a spectrum of distal lung
function abnormalities with risk factors for asthma severity, asthma
control, and physical activity.  2021 The Authors. Published by
Elsevier Inc. on behalf of the American Academy of Allergy, Asthma
& Immunology. This is an open access article under theCCBY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). (J
Allergy Clin Immunol Pract 2021;-:---)
Key words: Small airway dysfunction; Asthma control; Physical
activity; Structural equation modeling
INTRODUCTION
Asthma is a complex airway disease with different clinical
phenotypes and various factors that contribute to disease severity
and poor symptom control, specifically age,1 eosinophil mediatedairway inflammation,2 smoking,3 obesity,1 and small airway
dysfunction (SAD). Data suggest that SAD is highly prevalent in
asthma and present across patients with all disease severities.4-6
Small airway dysfunction is a distinct lung function abnormal-
ity that might present independent of airflow limitation in
symptomatic asthma patients.2 Previous studies demonstrated
associations between asthma control and indirect markers of
SAD, such as air trapping,3 ventilation heterogeneity,7 and
alveolar nitric oxide.8 Likewise, Shi and colleagues5 reported
associations between SAD measured by impulse oscillometry
(IOS) and poor symptom control in children with asthma.4,5
Furthermore, earlier data from our group suggested an associa-
tion between SAD and physical activity.6
Taken together, there is accumulating evidence that as in
other clinical factors, SAD might be linked to asthma severity
and poor symptom control. However, whether the clinical factors
and inflammatory phenotypes associated with poor asthma
control are ascribable to SAD or directly affect asthma control is
not fully clear. Besides, few observational studies assessed a broad
panel of clinical parameters such as IOS, inert gas washout,
sputum eosinophils, and accelerometry-based physical activity in
a cohort of asthmatic patients with different severities. Such
broad clinical characterization combined with advanced statistical
approaches such as structural equation modeling (SEM) might
be helpful unravelling the multidirectional associations and po-
tential causal pathways in complex clinical conditions.
Therefore, in this cross-sectional study, we aimed to find a
clinical model based on SEM that integrates the interrelations
among established risk factors of poor symptom control, SAD,
and physical activity. We hypothesized that SAD would have a
central role linking clinical and inflammatory characteristics of
asthma with symptom control and physical activity.METHODS
Study design
We carried out a cross-sectional analysis on baseline data of the
adult arm of the multicenter prospective longitudinal All Age
Asthma Cohort, a cohort of pediatric and adult patients with
asthma, initiated by the German Centre for Lung Research (DZL).9
The study was approved by a local ethics committee at the Luebeck
medical school (Az.21-215) and is registered at clinicaltrials.gov
(adult arm: NCT02419274). Written informed consent was ob-
tained before enrollment.
Since 2014, the adult arm of the All Age Asthma Cohort recruited
patients with mild to severe asthma and healthy controls. Until
February 2020, we recruited 268 adult asthma patients and 69
healthy subjects, all of whom were included in this analysis. Detailed
information on recruitment and inclusion and exclusion criteria were
described previously elsewhere.9 Inclusion criteria for healthy sub-
jects are listed in Table E1 (available in this article's Online Re-
pository at www.jaci-inpractice.org). To avoid significant selection
bias, current or former smokers with 10 or more pack-years smoking
history with an absence of dominant chronic obstructive pulmonary
disease features10 were included in the analysis. Patients had to have
stable disease without acute exacerbations or respiratory tract in-
fections within 4 weeks before the study visit.
Asthma patients were classified into mild to moderate or severe
disease according to European Respiratory Society/American
Thoracic Society guidelines.11 We assessed symptom control based
on the asthma control test (ACT), asthma control questionnaire, and
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defined as a burst of systemic corticosteroids for 3 or more days.11
Uncontrolled asthma was defined by a asthma control question-
naire result of 1.5 or greater or an ACT score of less than 20, or two
or more severe exacerbations or one serious exacerbation with hos-
pitalization, intensive care unit stay, or mechanical ventilation in the
previous year.11
Measures of small airway function
We performed IOS, body plethysmography, inert gas multiple
breath washout, and spirometry in accordance with current recom-
mendations.8,12-14 Corresponding measures and indirect markers of
small airway function were the frequency dependence of resistance
(FDR) (R5Hz-20 Hz) and lung reactance at 5 Hz (XHz) measured
by IOS, specific effective airway resistance, residual lung volume
(RV), and ratio of RV to total lung capacity (RV/TLC) measured by
body plethysmography, lung clearance index (LCI) measured by
multiple breath washout, and mean forced expiratory flow at 50%
and between 25% and 75% of the forced vital capacity (FVC)
(FEF50 and FEF25-75) from forced spirometry. Whereas the FDR is
considered a valid direct measure of anatomic narrowing in the small
airways of patients with asthma,15 the LCI is also a reference stan-
dard measure of ventilation distribution and a sensitive indicator of
early lung damage.14 Therefore, we used the FDR and LCI to study
the relation between SAD severity and asthma outcomes and applied
them in the SEM. Furthermore, we used the previously suggested
FDR abnormality cutoffs of greater than 0.03 KPa/L per s16-18 and
greater than 0.07 KPa/L per s2,19 to identify the prevalence of SAD
in the cohort. However, there are no generally accepted FDR cutoffs
to determine the severity of SAD. Therefore, we used the FDR
percentiles to define SAD severity. We classified asthma patients into
three groups based on FDR measures. No or mild SAD included
patients with the lowest measures below the 25th percentile; severe
SAD was patients with measures above the 75th percentile, whereas
moderate SAD included patients with measures between the 25th
and 75th percentiles.
Physical activity
Physical activity was measured over 1 week by a multisensory
activity monitor (SenseWear Pro Armband, BodyMedia, Pittsburgh,
PA), as previously described.6,20 We assessed the average steps per
day and average minutes of at least moderate activity per day (any
energy expenditure greater than 3 metabolic equivalents). A
threshold of 94% of wearing time (22.5 h) for at least 5 days was set
to identify valid analyses.20
Inflammatory markers
We studied type 2 inflammation by measuring eosinophil con-
centrations in blood and sputum as well as the fractional exhaled
nitric oxide (FeNO).21 Sputum induction and processing were
performed according to standardized operating procedures.22 We
included serum levels of high sensitivity C-reactive protein (hsCRP)
as a marker of low-grade, nonetype 2 systemic inflammation
commonly observed in obese asthma patients.23
Statistical analysis
We used one-way analysis of variance and Kruskal Wallis or
Fisher exact test to identify differences in clinical variables between
study groups. For pairwise comparison, a post hoc analysis with
Tukey’s test or Dunn’s test was done. To test for correlation between
two continuous variables, we used Pearson’s test or Spearman’s rank
test.To understand interrelations among the observed clinical vari-
ables, we performed path analyses using SEM, which is a compre-
hensive framework of statistical analysis that simultaneously
evaluates multiple regressions to estimate the direct effect that a
variable might have on an outcome as well as indirect pathways by
which an independent variable or a confounder might affect other
variables, which eventually would affect the outcome.24 The path
analyses aimed to appraise potential predictors of SAD and their
directional causality, evaluate interrelations among different small
airway function measures and finally, determine their subsequent
impact on asthma outcomes. The goodness of fit of the hypothesized
models was statistically evaluated by (1) c2 test and degrees of
freedom, in which the desired result is P greater than .05, which
indicates that the discrepancy between the hypothesized model and
the actual observed data is not significant, and that the remaining
unexplained variances do not affect the model fit; and (2) goodness
fit indices. For this, we used a standardized root mean square residual
less than 0.08 and a root mean square error of approximation
(RMSEA) less than 0.06 with a 90% confidence interval (CI), both
of which indicate how good the hypothesized model fits the
covariance matrix of observed data, and a comparative fit index
(CFI) of 0.95 or greater, which indicates the goodness of correlations
among the tested variables in the model.25,26 Maximum likelihood
was the method of estimation. Nonnormally distributed variables
were logarithmized and rescaled to reduce the skewness. Statistical
analyses were performed using R (version 3.6.2, R Foundation,
Vienna, Austria). An alpha error of less than 5% was considered
statistically significant.
RESULTS
We included 337 subjects, which included 140 patients with
mild to moderate asthma, 128 with severe asthma, and 69
healthy controls. Table I lists detailed clinical characteristics of
patients with asthma as well as those of healthy controls. Patients
with severe asthma were older and heavier, and had mild to
moderate airflow obstruction, more severe exacerbations, and
worse asthma control. Sputum eosinophils, blood eosinophils,
FeNO, and hsCRP were significantly elevated in both asthma
groups compared with healthy controls and in patients with se-
vere asthma compared with patients with mild to moderate
asthma; however, the blood eosinophils count was similar in both
asthma groups.
Measures of small airway function were significantly different
between asthma patients and healthy controls except for LCI and
RV, which were similar between patients with mild to moderate
asthma and healthy controls (Table II). Measures of small airway
resistance, air trapping, and ventilation heterogeneity correlated
with asthma severity (Table II). We also found that the corre-
lation between SAD (FDR) and airflow limitation (forced expi-
ratory volume in 1 second [FEV1]/FVC) was stronger in patients
with severe asthma (R ¼ e0.60) than in patients with mild to
moderate asthma (R ¼ e0.33).
The prevalence of SAD as identified with prespecified FDR
cutoffs of 0.07 and 0.03 KPa/L per s ranged from 75% to 90%
in patients with severe asthma, 53% to 64% in those with mild
to moderate asthma, and 16% to 45% in healthy controls.
Small airway dysfunction: contributing factors and
outcomes
Based on the percentiles of FDR, about 21% of patients with
asthma had no or mild SAD, 54% had moderate SAD, and 25%
TABLE I. Baseline clinical characteristics of patients with asthma and control participants*
Clinical characteristics Healthy (n [ 69) Mild to moderate asthma (n [ 128) Severe asthma (n [ 140) P
n 69 128 140 e
Age, y 41 (25-63) 48 (35-56) 54 (50-65) <.01
Sex (% female) 45 58 54 .22
Body mass index, kg/m2 23.5 (21.9-26.8) 26.0 (23.5-28.8) 28.1 (24.6-31.6) <.01
Current or former smokers >10 pack-y (%) e 20 20 .18
Pack-y 12.7 (2.75-19.5) 9 (4.25-20.0) .21
Short-acting b2-agonists only (%) e 20 0 <.01
ICS (%) e 14 5 <.01
ICS/long-acting b2-agonists (%) e 64 95 <.01
ICS dose, mg - 347 (100-500) 1000 (500-1000) <.01
Long-acting muscarinic receptor antagonists (%) e 6 50 <.01
Oral corticosteroids (%) e 0 45 e
Oral corticosteroid doses (mg prednisolone) e e 10 (5-12.0) e
FEV1 (%) 105 (95-110) 90 (77-103) 69 (57-86) <.01
FEV1/forced vital capacity (%) 76 (72-80) 71 (64-78) 59 (51-68) <.01
Sputum eosinophils count (%) 1.0 (0.0.-3.7) 0.8 (0.3-3.2) 3.4 (0.5-15.7) <.01
Blood eosinophil count, mL 150 (100-210) 280 (150-465) 300 (120-525) <.01
Fractional exhaled nitric oxide, ppb 15 (11-20) 20 (13-37) 33 (20-50) <.01
High-sensitivity C-reactive protein, mg/dL 0.06 (0.2 -1.4) 1.36 (0.68-2.43) 2.6 (1.0-5.3) .01
2 severe exacerbations (%)† e 19 66 <.01
Asthma control test score e 22 (18-24) 16 (11-20) <.01
Asthma control questionnaireefive-item score 0.71 (0.28-1.2) 2 (1-3) <.01
FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; ICS dose, fluticasone equivalent.
*Values are presented as median and interquartile range.
†Number of severe exacerbations within 12 months before study visit. The number of sputum samples in healthy controls and patients with mild to moderate and severe asthma
were 58, 112, and 107, respectively. The number of high-sensitivity C-reactive protein samples in healthy controls and mild to moderate and severe asthma patients was 47, 101,
and 93, respectively.
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tics and small airway function measures for each group. Patients
with severe SAD were older, had a higher body mass index
(BMI), and included the highest percentage of current and
former smokers as well as the highest percentage of patients
classified as severe or uncontrolled. Whereas patients with severe
SAD had higher hsCRP values compared with no/mild or
moderate SAD, markers of type 2 inflammation (sputum eo-
sinophils, blood eosinophils, and FeNO) were similar among the
different SAD severities (Table III). Inhaled corticosteroid dose
and use of oral corticosteroids increased with SAD severity.
Other lung function measures of SAD paralleled FDR impair-
ments (Table III). Physical activity as assessed by average daily
step counts and average time in at least moderate activity
decreased with SAD severity (Figure 1). The severity of SAD was
also associated with worse asthma control and increased numbers
of severe exacerbations (Figure 1; see Table E1 in this article’s
Online Repository at www.jaci-inpractice.org for correlations of
SAD, indicated by FDR and LCI, with the continuous clinical
variables).
Structural equation model
Clinical variables that correlated with either the severity of
asthma (Table I) or the severity of SAD (Tables III and E1,
Figure 1) were interrelated in structural equation models. Mea-
sures of SAD were the FDR, FEF25-75, RV, and LCI. Predictors
of SAD were age, obesity, systemic inflammation, smoking, and
type 2 inflammation markers, whereas anticipated outcomes
were symptom control and physical activity. In a best-fit model(Figure 2, A), age, obesity, and obesity-related systemic inflam-
mation (hsCRP) were predictors of FDR. Moreover, in this
model, blood eosinophils as a surrogate for type 2 inflammation
demonstrated a statistically nonsignificant regression with FDR
(Table IV); therefore, a direct contribution of blood eosinophils
to increased FDR could not be confirmed. No tested predictors
of FDR affected each other except for obesity, which contributed
to systemic inflammation. Furthermore, FDR was the main
determinant of symptom control followed by obesity. The model
showed that obesity and physical activity affect each other in a
bidirectional relationship. Likewise, the relation between physical
activity and symptom control was also bidirectional. In addition,
the model suggests that the negative effect of FDR on physical
activity is mainly mediated through the impact of FDR on
symptom control. However, the model also indicates that FDR
and physical activity affect each other in a bidirectional rela-
tionship. The model had an excellent fit with a CFI of 0.984, an
RMSEA of 0.026 (90% CI, 0.0-0.083), a standardized root
mean square residual of 0.057, and a c2 value of 14.521,
(P¼ .34). In an alternative model, we studied the relevance of
type 2 inflammation in SAD using sputum eosinophils instead of
blood eosinophils. Here, a statistically significant regression be-
tween sputum eosinophils and SAD could be observed (P < .01).
This alternative model showed a good fit with a CFI of 0.968, an
RMSEA of 0.050 (90% CI, 0.0-0.12), and c2 P ¼ .24, and the
standardized estimation coefficient of sputum eosinophils was
0.219. Considering FeNO as a surrogate for type 2 inflammation
worsened the overall model fit (CFI ¼ 0.90) and the regression
between FeNO and SAD was also statistically nonsignificant
TABLE II. Measures of small airway function in patients with asthma and healthy controls*
Variable Healthy Mild to moderate asthma Severe asthma P
FDR (R5-R20), KPa/L per s 0.03 (0.01-0.06) 0.08 (0.04-0.14) 0.15 (0.07-0.25) <.01
Reactance at 5 Hz e0.08 (e0.0 to 0.06) e0.12 (e0.18 to 0.09) e0.18 (e0.27 to 0.11) <.01
Forced expiratory flow at 25% and 75% of forced vital capacity, L/s 2.9 (2.0-3.8) 1.8 (1.3-2.6) 0.9 (0.5-1.4) <.01
Forced expiratory flow at 50% of forced vital capacity (%) 90 (74-103) 58 (38-79) 31 (19-48) <.01
Residual volume (%) 110 (100-119) 110 (98-12) 141 (111-165) <.01
Residual volume/total lung capacity 31 (26-37) 35 (29-40) 44 (37-51) <.01
Specific effective airway resistance (%) 67 (56-84) 91 (67-130) 136 (99-218) <.01
Lung clearance index 5.7 (5.2-6-0) 6.1 (5.4-6.9) 7.4 (7.0-8.3) <.01
Small airway dysfunction prevalence (FDR > 0.07) (%) 16 53 75 <.01
Small airway dysfunction prevalence (FDR > 0.03) (%) 46 64 90 <.01
FDR, frequency dependence resistance.
*Values are presented as median and interquartile range. Lung clearance index measures are from 47 healthy controls and 88 mild to moderate and 91 severe asthma patients.
TABLE III. Clinical characteristics and small airway function in asthma patients based on SAD severity*
Characteristic No or mild SAD (n [ 55) Moderate SAD (n [ 145) Severe SAD (n [ 68) P
Age, y 47 (34-54) 53 (45-65) 56 (48-65) <.01
Body mass index, kg/m2 23.6 (22.2-26.4) 27.3 (24.6-29.7) 28.8 (24.7-34.6) <.01
Female sex (%) 67 50 41 .09
Current or former smokers >10 pack-y (%) 14 20 35 .018
Severe asthma (%) 34 49 72 <.01
Uncontrolled symptoms (%) 43 51 81 <.01
>2 severe exacerbations (%) 20 29 47 <.01
High-sensitivity C-reactive protein, mg/dL 1.2 (0.5-2.1) 1.6 (0.8-3.1) 3.3 (1.1-6.3) .01
Blood eosinophil count, mL 220 (140-430) 300 (150-542) 305 (138-572) .46
Sputum eosinophils (%) 0.8 (0.2-4.9) 1.7 (0.4-8.9) 2 (0.5-13.0) .16
Fractional exhaled nitric oxide, ppb 27 (15-46) 28 (17-45) 25 (14-43) .53
Inhaled corticosteroids dose, mg 400 (100-500) 500 (250-585) 800 (400-1000) <.01
Oral corticosteroids (%) 16 23 32 .17
Measures of small airway function
Frequency dependence resistance (R5-20), KPa/L per s 0.02 (0.1-0.03) 0.10 (0.07-0.15) 0.26 (0.24-0.36) <.01
Reactance at 5 Hz e0.09 (0.11-0.07) e0.14 (e0.18 to 0.10) e0.31 (e0.38 to 0.24) <.01
Forced expiratory flow at 25% and 75% of forced
vital capacity, L/s
2.2 (1.5-2.9) 1.5 (0.8-2.2) 0.63 (0.44-1.0) <.01
Forced expiratory flow at 50% of forced vital capacity (%) 63 (46-89) 58 (29-71) 22 (14-34) <.01
Lung clearance index 6.1 (5.4-6.5) 6.4 (5.8-7.1) 7.9 (6.8-8.9) <.01
Specific effective airway resistance (%) 73 (59-102) 103 (77-137) 224 (166-291) <.01
Residual volume (%) 106 (96-127) 123 (102-145) 149 (124-176) <.01
Residual volume/total lung capacity (%) 35 (26-37) 38 (33-44) 48 (41-58) <.01
SAD, Small airway dysfunction
*Values are presented as median and IQR. The age difference was not statistically significant between severe and moderate SAD. Measures of reactance at 5 Hz were
comparable between patients with no or mild and moderate SAD (P > .05). The number of measures in patients with no or mild, moderate, and severe SAD for high-sensitivity
C-reactive protein was 36, 104, and 54, for sputum eosinophil counts of 51, 120, and 48, for a lung clearance index of 38, 94, and 47, respectively.
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SAD.
In a further model (Figure 2, B), we included the LCI as main
indicator of SAD. Age and sputum eosinophils, but not obesity,
were direct predictors of LCI. This model also showed that LCI
is mainly affected by distal lung function abnormality, as indi-
cated by air trapping (RV), which in turn was mainly affected by
distal airflow limitation (FEF25-75). However, the model also
indicated that central airflow limitation might contribute to
ventilation heterogeneity (LCI). The effect of smoking (number
of pack-years) on LCI was mediated by its contribution to air
trapping. This model also confirmed the bidirectional associationbetween asthma control and physical activity, and between
physical activity and obesity. The model had a very good fit, with
a CFI of 0.978, RMSEA of 0.038 (90% CI, 0.0-0.084), and c2
P ¼ .24.DISCUSSION
The main finding of our study is that SAD is a prevalent
feature of asthma that entails a spectrum of interrelated distal
lung function abnormalities that link multiple risk factors of
asthma severity with asthma control and physical activity. Older
age, obesity, and subsequent systemic inflammation, T2
FIGURE 1. Asthma outcomes in asthma patients classified based on small airway dysfunction (SAD) severity. (A) Distribution of average
daily steps. (B) Distribution of average daily time of at least moderate activity. (C) Differences in asthma control test score. (D) Differences
in asthma control questionnaireefive item (ACQ5) score. (E) Annualized severe exacerbations. Means  SD of average daily steps were
9647  4110 for mild SAD, 7659  3111 for moderate SAD, and 6717  2890 for severe SAD, respectively. Means  SD of average daily
time in moderate activity were 172  108 for mild SAD, 140  82 for moderate SAD, and 115  80 for severe SAD, respectively. All
pairwise comparison in all groups were statistically significant except for average daily time of moderate activity and number of exac-
erbations between patients with mild and moderate SAD.
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predictors of SAD. The SEM suggests that the negative impact of
SAD on physical activity is mainly mediated by the worsening of
symptoms. Furthermore, it highlights important bidirectional
associations of physical activity with SAD and asthma control.
In this cohort, the prevalence of SAD in asthma correlated
with asthma severity and was comparable to the prevalence inprevious studies.16,17,27 We demonstrated a prevalence of 53%
to 90% at FDR cutoffs of greater than 0.07 and greater than
0.03 KPa/L per s, respectively. Based on an FDR cutoff of greater
than 0.03 Anderson and colleagues17 demonstrated prevalence
rates that ranged from 65% to 70% in 378 asthma patients who
were treated according to British Thoracic Society asthma
treatment steps 2 to 4. At that cutoff, the prevalence ranged
FIGURE 2. Structural equation model. (A) The first model with frequency dependence of resistance (FDR) as a single indicator of small
airway dysfunction (SAD). (B) The second model displaying forced expiratory flow at 25% and 75% of the forced vital capacity (FEF25-
75), residual volume (RV), and lung clearance index (LCI) as indicators of SAD. For regression and correlation coefficients, see Table IV.
Unidirectional arrows indicate linear regression and double-headed arrows indicate correlations between two variables. Rectangles
indicate that all variables were observable. Significant correlations are represented with continues arrows. Dashed arrows illustrate re-
gressions and correlations with P values greater than .05 for the Z-statistic. Asterisks mark variables from alternative models. (A) il-
lustrates that SAD links the negative impacts of age, type 2 inflammation, and obesity to asthma control. Poor symptom control and
physical inactivity display a bidirectional correlation. (B) illustrates interrelations among multiple measures of lung function in which the
LCI is a global indicator of ventilation heterogeneity. ACT, asthma control test; BMI, body mass index; FeNO, fractional exhaled nitric
oxide; hsCRP, high-sensitivity C-reactive protein; py, pack-years.
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Airways Involvement in Asthma (ATLANTIS) cohort, in which
the prevalence also correlated with asthma severity defined by the
Global Initiative for Asthma (GINA) treatment classes 1 to 5.16
Interestingly, we also observed a prevalence of about 46% of
SAD in healthy controls when referring to the lower cutoff of
0.03 KPa/L per s, which might be explained by the prevalence of
overweight, because 16% of healthy controls who were demon-
strated to have SAD at a cutoff of 0.07 KPa/L per s also had
significantly higher BMI values (mean, 26.5 kg/m2) compared
with healthy controls without SAD (BMI mean, 23.0 kg/m2).
This finding supports the notion that SAD is a distinct patho-
logic trait associated with obesity and could serve as an inde-
pendent feature to characterize patients with asthma while not
being strictly pathognomonic for the disease itself. In addition,
this finding is in line with previous results that indicated a close
association of IOS-defined SAD with overweight and obesity,
irrespective of the presence of asthma, in a population of children
and young adolescents.28 It also supports the findings that SAD
might be present in healthy obese subjects, despite having
normal spirometry.29 In asthma, a recent study30 suggested that
overweight is among the strongest predictors of IOS-defined
SAD. Consistently, our data show that obese and overweight
asthma patients tend to have more severe SAD, worse symptom
control, and elevated markers of systemic inflammation.
Furthermore, our SEM indicates that increases in weight directly
contribute to SAD, which might best be explained by mechanical
compression, as indicated by earlier studies.31 Interestingly, it
also indicates an indirect contribution to SAD through systemic
inflammation. However, there is no evidence that hsCRP per se
contributes to SAD, yet it might be a surrogate that reflects a
status of chronic low-grade systemic inflammation with elevatedadipokines, which might in turn have a role in airway inflam-
mation.23,32 The impact of obesity on asthma control and
physical inactivity was not only mediated by SAD. According to
our model, there was still a direct impact of obesity itself on both
asthma control and physical inactivity. This finding was in line
with previous findings indicating that obesity is associated with
poor symptom control and low physical activity in asthma.33 It is
also noteworthy that BMI was a main predictor of FDR but not
a direct predictor of LCI. This can be confirmed by findings
showing that age might influence the LCI, whereas no impact of
height or weight was found.34
In our study, markers of type 2 inflammation showed a ten-
dency to be elevated in patients with severe SAD. because pa-
tients with severe SAD also had an intensified treatment with
either inhaled or oral corticosteroids, the relation between SAD
and type 2 inflammation might have been underestimated by our
model. Nevertheless, our SEM indicated that sputum eosinophil
count is an independent predictor of FDR and LCI. The po-
tential role of type 2 inflammation in SAD is consistent with
previous findings that in severe asthma, small airways are
significantly infiltrated with activated eosinophils, and that the
degree of infiltration is even more pronounced compared with
the large airways.35 Furthermore, the assessment of SAD severity
using the FDR was recently observed to be useful in monitoring
treatment response to anti-eosinophil biological therapy in severe
eosinophilic asthma.36
Age has been linked to poor symptom control and increased
risk for exacerbation, which is usually explained by the preva-
lence of comorbidities and nonadherence to treatment among
elderly asthmatic patients.37,38 However, our models suggest that
age is a factor that directly affects SAD, which in turn has an
impact on asthma control. Indeed, our observation is compatible
TABLE IV. Results of structural equation models*
Path Standardized estimates Standard error P
Model 1: FDR as indicator of SAD
hsCRP ) BMI 0.290 0.07 .00
FDR ) Blood eosinophils 0.090 0.02 .18
FDR ) BMI 0.199 0.018 .006
FDR ) Age 0.186 0.006 .007
FDR ) hsCRP 0.261 0.019 .00
FDR ) Smoking (pack-y) e0.047 0.007 .49
ACT ) FDR e0.270 0.34 .00
ACT ) BMI e0.180 0.085 .015
SPD 4 FDR e0.200 0.003 .007
SPD 4 ACT 0.172 0.014 .018
SPD 4 BMI e0.292 0.015 .00
Model 2: FEF25-75, RV, and LCI as indicators of SAD
RV ) FEF25-75 e0.606 0.002 .00
RV ) Age e0.218 0.016 .004
RV ) Smoking (pack-y) 0.177 0.016 .012
LCI ) Age 0.206 0.062 .001
LCI ) RV 0.388 0.336 .00
LCI ) FEV1 e0.297 0.051 .00
LCI ) Sputum eosinophils 0.146 0.048 .023
LCI ) BMI e0.018 0.17 .77
ACT ) LCI e0.301 0.036 .001
ACT ) FEV1 0.201 0.025 .022
ACT ) BMI e0.111 0.087 .14
ACT 4 SPD 0.205 0.001 .014
SPD 4 BMI e0.292 0.002 .001
ACT, asthma control test; BMI, body mass index; FDR, frequency dependence resistance (R5-20); FEF25-75, forced expiratory flow at 25% and 75% of forced vital capacity;
hsCRP, high-sensitivity C-reactive protein; LCI, lung clearance index; RV, residual volume, SAD, small airway dysfunction; SPD, steps per day.
*The upper panel represents the path analysis of the first model and the second model is represented in the lower panel. Results of corresponding statistical tests are on the right
side of each panel. Statistical results include the standardized estimate of the regression and correlation coefficients, the standard error of the unstandardized coefficients (not
shown), and the P value are given for the Z-statistic. P  .05 provides the likely relevance of that variable. Unidirectional arrows indicate a relation in terms of a linear
regression; double-headed arrows indicate a correlation between variables.
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a higher prevalence of SAD in elderly asthmatic patients
compared with those who were not elderly.39 Because aging itself
leads to a decrease in the elastic recoils of the lung, a reduction in
the supporting tissue that surrounds the distal lung parenchyma
may thus increase the instability and collapsibility of the small
airways. Our data suggest that age will remain a relevant factor of
asthma control through its impact on SAD irrespective of other
confounders related to older age, such as poor therapy adherence.
In our study, the distribution of current or former smokers
was significantly higher in severe SAD than in no/mild or
moderate SAD. Our SEM also suggests that in terms of the
number of pack-years, smoking was an indirect predictor of
ventilation heterogeneity through its contribution to distal
airflow limitation (FEF25-75) and air trapping; this is consistent
with the recently suggested association between cigarette smok-
ing and spirometry-defined SAD in a large population study.40
However, our model did not show a statistically significant
correlation between smoking quantity and the FDR.
Interestingly, the negative impact of SAD on physical activity
in our model was mainly mediated by poor symptom control
(ie, the patient’s perception of the illness). Patients engage in
low physical activity to avoid unpleasant symptoms such as
shortness of breath and chest tightness. However, the model
also indicates that the relation between physical activity andsymptom control is bidirectional, which suggests that increased
physical activity improves asthma control. This finding is
compatible with findings that regular and structured exercise
interventions improve asthma control and patients’ quality of
life.41,42 Likewise, SAD also showed a bidirectional association
with physical activity. Although the impact of SAD on physical
activity can be explained by their interaction with symptom
control, the proposed positive impact of physical activity on
SAD remains unclear. So far, clinical studies on asthma patients
suggested a limited impact of physical activity on airflow limi-
tation.41-43 We previously demonstrated a stronger association
of physical activity with the FDR than with airflow limitation,6
which warrants further studies to evaluate whether the positive
impact of physical activity on asthma control is attributable to
improvements in SAD. Furthermore, our model confirms a
strong bidirectional relation between obesity and physical ac-
tivity that was proposed by several studies.44,45 Moreover, the
model describes the interrelation among different SAD mea-
sures, because it confirmed that FEF25-75 is a strong predictor of
air trapping,46 which in turn affects the heterogeneity of
ventilation. However, ventilation heterogeneity might also
result from air flow limitation in the large airways, as measured
by FEV1, and also depends on the residual volume of the
lung.47-50 Overall, the models indicate some discrepancies
regarding predictors of different SAD measures. This is
J ALLERGY CLIN IMMUNOL PRACT
VOLUME -, NUMBER -
ABDO ETAL 9particularly interesting because it suggests that SAD is a
comprehensive term describing a spectrum of related distal lung
function abnormalities with possibly distinct subtypes and
diverse causing etiologies.
Our study also has limitations. First, a cross-sectional study
does not allow the causality to be inferred. However, an SEM
with excellent fit indices is frequently applied to overcome this
limitation. Second, the lack of adipokines in our analysis did not
allow a proper understanding of the role of systemic inflamma-
tion in SAD. Third, the impact of type 2 inflammation on SAD
might have been underestimated by our cross-sectional model,
because underlying therapies reducing type 2 inflammation were
intensified in patients with severe SAD. Finally, there is no
formal power calculation underlying our analysis on SAD.
However, based on the available literature with a comparable
number of subjects,17,27,30 and the good model fit, we believe
that our data provide a reliable analysis. Furthermore, to the
authors’ knowledge, this is the first study to demonstrate risk
factors for SAD and its outcomes in one integrated model,
including measures of physical activity as an objective indicator
of lifestyle restriction in patients with asthma.
Summary
Small airway dysfunction is a prevalent feature of asthma that
entails a spectrum of distal lung function abnormalities that
strongly correlates with asthma outcomes. Our data propose that
SAD is a key feature of asthma in which the frequently observed
risk factors for disease severity are interrelated with symptom
control and physical activity.
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ABDO ETAL 10.e1ONLINE REPOSITORYTABLE E1. Correlations of FDR and LCI with continuous clinical variables
Clinical variable Correlation coefficient P
Correlations of clinical variables with frequency dependence resistance
Age, y 0.32 <.001
Body mass index, kg/m2 0.35 <.001
Smoking, pack y 0.11 .09
High-sensitivity C-reactive protein, mg/dL 0.22 <.01
Blood eosinophils count, mL 0.05 .54
Sputum eosinophils (%) 0.12 .07
Fractional exhaled nitric oxide, ppb 0.04 .55
Severe exacerbations, n 0.15 .014
Asthma control test score e0.35 <.001
Asthma control questionnairee5-item score 0.34 <.001
Average daily steps e0.33 <.001
Average daily time of at least moderate activity, min e0.21 <.01
Correlations of clinical variables with lung clearance index
Age, y 0.26 <.001
Body mass index, kg/m2 0.06 .40
Smoking, pack-y 0.12 .09
High-sensitivity C-reactive protein, mg/dL 0.12 .14
Blood eosinophils count, mL 0.12 .09
Sputum eosinophils (%) 0.34 <.001
Fractional exhaled nitric oxide, ppb 0.15 .047
Severe exacerbations, n 0.34 <.001
Asthma control test score e0.45 <.001
Asthma control questionnairee5-item score 0.49 <.001
Average daily steps e0.17 .026
Average daily time of at least moderate activity, min e0.12 .09
Inclusion criteria for healthy controls were age 18 years or older, no respiratory symptoms consistent with asthma or chronic obstructive pulmonary disease, and normal
spirometry.
